CL2024002724A1 - Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson - Google Patents

Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson

Info

Publication number
CL2024002724A1
CL2024002724A1 CL2024002724A CL2024002724A CL2024002724A1 CL 2024002724 A1 CL2024002724 A1 CL 2024002724A1 CL 2024002724 A CL2024002724 A CL 2024002724A CL 2024002724 A CL2024002724 A CL 2024002724A CL 2024002724 A1 CL2024002724 A1 CL 2024002724A1
Authority
CL
Chile
Prior art keywords
parkinson
disease
mhc
synuclein
specific tolerance
Prior art date
Application number
CL2024002724A
Other languages
English (en)
Spanish (es)
Inventor
Wischhusen Jörg
Bruttel Valentin
Wang IP Chi
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of CL2024002724A1 publication Critical patent/CL2024002724A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2024002724A 2022-03-24 2024-09-11 Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson CL2024002724A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22164123.6A EP4249506A1 (en) 2022-03-24 2022-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
CL2024002724A1 true CL2024002724A1 (es) 2025-02-14

Family

ID=81384775

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002724A CL2024002724A1 (es) 2022-03-24 2024-09-11 Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson

Country Status (12)

Country Link
US (1) US20250205321A1 (https=)
EP (2) EP4249506A1 (https=)
JP (1) JP2025514872A (https=)
KR (1) KR20240162549A (https=)
CN (1) CN119317639A (https=)
AU (1) AU2023238805A1 (https=)
CA (1) CA3250917A1 (https=)
CL (1) CL2024002724A1 (https=)
CO (1) CO2024012329A2 (https=)
IL (1) IL314741A (https=)
MX (1) MX2024011665A (https=)
WO (1) WO2023180548A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024344683A1 (en) * 2023-09-22 2026-04-02 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Also Published As

Publication number Publication date
MX2024011665A (es) 2024-09-27
CA3250917A1 (en) 2023-09-28
EP4249506A1 (en) 2023-09-27
CN119317639A (zh) 2025-01-14
WO2023180548A1 (en) 2023-09-28
IL314741A (en) 2024-10-01
AU2023238805A1 (en) 2024-07-18
EP4499682A1 (en) 2025-02-05
CO2024012329A2 (es) 2024-09-30
JP2025514872A (ja) 2025-05-12
KR20240162549A (ko) 2024-11-15
US20250205321A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
JOP20230167A1 (ar) مساعدات مستقبل gpcr، وتركيبات صيدلانية تشتمل عليها، وطرق استخدامها
CL2024002724A1 (es) Inducción de tolerancia específica de alfa-sinucleína mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
CO2025000513A2 (es) Anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1, composiciones que comprenden anticuerpos anti-ror1 o conjugados de anticuerpos anti-ror1 y métodos para hacer y usar anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1
BR112021009856A8 (pt) Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
DOP2025000021A (es) Proteínas y conjugados de unión al receptor de transferrina
AR063760A1 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
CL2021000207A1 (es) Nuevas proteínas de fusión específicas para cd137 y pd-l1
CU23403A1 (es) Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
ECSP20082338A (es) Receptores del factor de crecimiento quimérico
MX2022001682A (es) Nuevos formatos de moleculas de union a antigenos.
CL2022003205A1 (es) Cisteína proteasa
CO2024013220A2 (es) Inmunosupresión específica de mielina mediada por el mhc ib como un nuevo tratamiento para la esclerosis múltiple y la enfermedad por anticuerpos mog
CL2023003893A1 (es) Semaglutida para el tratamiento de esteatohepatitis no alcohólica.
ECSP21060605A (es) Vectores víricos que codifican variantes del fviii recombinantes con mayor expresión para la genoterapia de la hemofilia a
CO2024012332A2 (es) Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo
CO2024003578A2 (es) Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos
CO2026004947A2 (es) Proteínas de unión al receptor de transferrina y usos de estas
BR112021021210A2 (pt) Conjunto de polipeptídeos, método para gerar um polipeptídeo heterodimérico, primeiro polipeptídeo precursor heterodimérico, segundo polipeptídeo precursor heterodimérico e composição farmacêutica
CO2024012945A2 (es) Inmunosupresión específica del antígeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1
CO2025009946A2 (es) Proteínas de unión al antígeno anti-tnfr2 y sus usos
AR051928A1 (es) Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas
PE20080674A1 (es) Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico
MX2021009767A (es) Moleculas de union de fmcr y usos de las mismas.